#WCLC21: As­traZeneca's EGFR in­hibitor Tagris­so cuts re­lapse, death risks in pa­tients with and with­out pri­or chemother­a­py

As­traZeneca’s Tagris­so has es­tab­lished a strong foothold in non-small cell lung can­cer — the largest sec­tion of the lung can­cer com­mu­ni­ty — with mul­ti­ple ap­provals in the ear­ly set­ting. Those ap­provals in­clude pa­tients with re­moved tu­mors, an in­di­ca­tion where physi­cians have gone back and forth on the use of chemother­a­py.

Now, As­traZeneca may have an an­swer for the chemo de­bate: It doesn’t re­al­ly mat­ter in terms of our drug’s ef­fi­ca­cy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.